CLAIMS

1. An anti-fractalkine antibody or fractalkine~~FKN~~-binding fragment thereof, wherein the antibody or fragment thereof comprises:

(a) a CDR-H1 consisting of ~~comprising~~ the amino acid sequence of SEQ ID NO: 28;

(b) a CDR-H2 consisting of~~comprising~~ the amino acid sequence of SEQ ID NO: 29;

(c) a CDR-H3 consisting of~~comprising~~ the amino acid sequence of SEQ ID NO: 30;

(d) a CDR-L1 consisting of~~comprising~~ the amino acid sequence of SEQ ID NO: 31;

(e) a CDR-L2 consisting of~~comprising~~ the amino acid sequence of SEQ ID NO: 32; and

(f) a CDR-L3 consisting of~~comprising~~ the amino acid sequence of SEQ ID NO: 33.

2. The antibody of claim 1, wherein the antibody is an intact antibody.

3. The antibody or fractalkine~~FKN~~-binding fragment thereof of claim 1 or 2, wherein the antibody or fractalkine~~FKN~~-binding fragment is humanized.

4. The antibody or fractalkine~~FKN~~-binding fragment thereof of claim 3, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain variable domain of said antibody or fractalkine~~FKN~~-binding fragment comprises the amino acid sequence of SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 42, or SEQ ID NO: 43, and wherein the light chain variable domain of said antibody or fractalkine~~FKN~~-binding fragment comprises the amino acid sequence of SEQ ID NO: 38, SEQ ID NO: 44, or SEQ ID NO: 45.

5. The antibody or fractalkine~~FKN~~-binding fragment thereof of claim 1, 2, 3, or 4, wherein the antibody or fractalkine~~FKN~~-binding fragment is chimeric.

6. The antibody or fractalkine~~FKN~~-binding fragment thereof of claim 5, wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain variable domain of said antibody comprises the amino acid sequence of SEQ ID NO: 26, and wherein the light chain variable domain of said antibody comprises the amino acid sequence of SEQ ID NO: 27.

7. An anti-fractalkine antibody or fractalkine-binding fragment thereof, wherein the antibody or fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 37 and a light chain comprising the amino acid sequence of SEQ ID NO: 44.

~~7~~8. The antibody or fractalkine~~FKN~~-binding fragment thereof of any one of claims 1-~~6~~7, comprising a human constant region.

~~8~~9. The antibody or fractalkine~~FKN~~-binding fragment thereof of claim ~~7~~8, comprising a constant region of an IgG isotype.

~~9~~10. The antibody or fractalkine~~FKN~~-binding fragment thereof of claim ~~8~~9, comprising a constant region of the IgG2 isotype.

~~10~~11. The antibody or fractalkine~~FKN~~-binding fragment thereof of any one of claims 1-~~9~~10, comprising a mutated Fc region such that said antibody has reduced ADCC and/or complement activation.

~~11~~12. The antibody or fractalkine~~FKN~~-binding fragment thereof of claim ~~10~~11, wherein the Fc region is mutated at one or more of V234, G237, C131, or C219.

~~12~~13. The antibody or fractalkine~~FKN~~-binding fragment thereof of any one of claims 1 or claims 3 to ~~9~~10, wherein the fractalkine~~FKN~~-binding fragment is selected from the group consisting of a Fab, a Fab', a F(ab')2, and a Fv, and wherein the fractalkine~~FKN~~-binding fragment retains the binding specificity to fractalkine.

~~13~~14. The antibody or fractalkine~~FKN~~-binding fragment thereof of any one of claims 1-~~12~~13, wherein the antibody inhibits the binding between fractalkine and CX3CR1.

15. The antibody or fractalkine-binding fragment thereof according to any one of claims 1-14, for use in treating an inflammatory disorder, wherein the inflammatory disorder is ulcerative colitis, Crohn's disease, or rheumatoid arthritis.

~~14~~16. A pharmaceutical composition comprising the antibody or fractalkine~~FKN~~-binding fragment thereof of any one of claims 1-~~13~~15.

17. The pharmaceutical composition of claim 16, for use in treating an inflammatory disorder, wherein the inflammatory disorder is ulcerative colitis, Crohn's disease, or rheumatoid arthritis.

~~15~~18. The pharmaceutical composition of claim ~~14~~16 or 17, wherein the composition further comprises a carrier.

~~16~~19. The pharmaceutical composition of any one of claims ~~14 or 15~~16-18, wherein the composition further comprises an additional therapeutic agent.

~~17~~20. A nucleic acid encoding the antibody or fractalkine~~FKN~~-binding fragment thereof of any one of claims 1-~~13~~15.

~~18~~21. The nucleic acid of claim ~~17~~20, wherein said nucleic acid encodes all or a portion of the heavy chain of said antibody or fractalkine~~FKN~~-binding fragment thereof.

~~19~~22. The nucleic acid of claim ~~17~~-20or ~~18~~21, wherein said nucleic acid encodes all or a portion of the light chain of said antibody or fractalkine~~FKN~~-binding fragment thereof.

~~20~~23. A vector comprising the nucleic acid of any one of claims ~~17~~20-~~19~~22.

~~21~~24. The vector of claim ~~20~~23, wherein the vector is an expression vector.

~~22~~25. A host cell comprising one or more vectors of claim ~~20~~-23or ~~21~~24.

~~23~~26. The host cell of claim ~~22~~25, wherein said host cell comprises a first and second vector, said first vector comprising a nucleic acid encoding a heavy chain and said second vector comprising a nucleic acid encoding a light chain of the antibody or fractalkine~~FKN~~-binding fragment thereof of any one of claims 1-~~13~~15.

~~24~~27. The host cell of claim ~~23~~26, wherein expression of said heavy and light chain in said host cell produces an antibody or fractalkine~~FKN~~-binding fragment thereof of any one of claims 1-~~13~~15.

~~25~~28. The host cell of any one of claims ~~22~~25-~~24~~27, wherein the host cell is prokaryotic.

~~26~~29. The host cell of any one of claims ~~22~~25-~~24~~27, wherein the host cell is eukaryotic.

~~27~~30. The host cell of claim ~~26~~29, wherein the host cell is mammalian.

~~28~~31. The host cell of claim ~~27~~30, wherein the cell is a CHO cell or NS0 cell.

~~29~~32. A method for making an anti-fractalkine antibody or fractalkine~~FKN~~-binding fragment thereof, said method comprising (a) expressing the vector of any one of claim ~~20~~ 23or ~~21~~-24in a suitable host cell, and (b) recovering the antibody or fractalkine~~FKN~~-binding fragment thereof.

~~30~~33. The method of claim ~~29~~32, wherein said antibody or fractalkine~~FKN~~-binding fragment thereof is secreted by said host cell into culture media.

~~31~~34. The method of claim ~~30~~33, wherein said antibody or fractalkine~~FKN~~-binding fragment thereof is purified to at least 95% or greater with respect to said antibody-containing culture media.

~~32. A method for treating an inflammatory disorder comprising administering an effective amount of the antibody or FKN-binding fragment thereof of any one of claims 1-13 to a subject in need of such treatment, whereby the inflammatory disorder is treated.~~

~~33. The method of claim 32, wherein said inflammatory disorder is ulcerative colitis, Crohn's disease, rheumatoid arthritis, autoimmune hepatitis, multiple sclerosis, or neuropathic pain.~~

~~34. An anti-fractalkine antibody or FKN-binding fragment thereof, wherein the antibody or fragment thereof comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 37 and a light chain comprising the amino acid sequence of SEQ ID NO: 44.~~

~~35. An antibody or FKN-binding fragment thereof according to any one of claims 1-13 or claim 34 for use in treating an inflammatory disorder.~~

~~36. An antibody or FKN-binding fragment thereof of claim 35, wherein the inflammatory disorder is ulcerative colitis, Crohn's disease, rheumatoid arthritis, autoimmune hepatitis, multiple sclerosis, or neuropathic pain.~~

~~37~~35. The use of an antibody or fractalkine~~FKN~~-binding fragment thereof according to any one of claims 1-~~13~~ 15 ~~or claim 34~~ in the preparation of a medicament for use in treating an inflammatory disorder, wherein the inflammatory disorder is ulcerative colitis, Crohn's disease, or rheumatoid arthritis.

~~38. The use of claim 37, wherein the inflammatory disorder is ulcerative colitis, Crohn's disease, rheumatoid arthritis, autoimmune hepatitis, multiple sclerosis, or neuropathic pain.~~